Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
- 1 February 1999
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 353 (9154), 717-719
- https://doi.org/10.1016/s0140-6736(98)04474-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Human P450 metabolism of warfarinPharmacology & Therapeutics, 1997
- Genetic analysis of the human cytochrome P450 CYP2C9 locusPharmacogenetics, 1996
- Bleeding During Antithrombotic Therapy in Patients With Atrial FibrillationArchives of Internal Medicine, 1996
- [22] CYP2D6 multiallelismMethods in Enzymology, 1996
- Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapyPharmacogenetics, 1995
- Detection of CYP2C9 polymorphism based on the polymerase chain reaction in ChinesePharmacogenetics, 1995
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial FibrillationArchives of Internal Medicine, 1994
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994
- High clearance of (S)‐warfarin in a warfarin‐resistant subject.British Journal of Clinical Pharmacology, 1993
- Stereoselective interaction between the R enantiomer of warfarin and cimetidine.British Journal of Clinical Pharmacology, 1986